Abstract
Plasma biomarkers for Alzheimer’s disease (AD) are increasingly being used to assist in making an etiological diagnosis for cognitively impaired (CI) individuals or to identify cognitively unimpaired (CU) individuals with AD pathology who may be eligible for prevention trials. However, a better understanding of the timing of plasma biomarker changes is needed to optimize their use in clinical and research settings. The aim of this study was to evaluate the timing of change of key AD plasma biomarkers (Aβ42/Aβ40, p-tau181, p-tau217, GFAP and NfL) from six different companies, along with established AD biomarkers, using AD progression timelines based on amyloid and tau PET.
We used data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), including 784 individuals with longitudinal amyloid PET and 359 individuals with longitudinal tau PET, to estimate age at amyloid and tau positivity, defined as the age at the first positive PET scan ([18F] florbetapir amyloid PET SUVR>0.78, [18F] flortaucipir tau PET SUVR>1.41, respectively). Of these, 190 individuals with an estimated age at amyloid positivity and 70 individuals with an estimated age at tau positivity had longitudinal plasma biomarker measures. Age at tau positivity was a stronger predictor of symptom onset than age at amyloid positivity in 17 individuals who progressed from CU to CI during their participation in the ADNI study (Adj R2 = 0.86 vs. Adj R2 = 0.38), therefore was used to estimate symptom onset age for all individuals with an estimated age at tau positivity. Generalized additive mixed models (GAMMs) were used to model biomarker trajectories across years since amyloid positivity, tau positivity, and symptom onset, and to identify the earliest timepoint of biomarker abnormality when compared to a reference group of amyloid and tau PET-negative CU individuals, as well as time periods of significant change in biomarkers.
All plasma biomarkers except NfL became abnormal prior to amyloid and tau positivity. Plasma Aβ42/Aβ40 was the first biomarker to reach abnormality consistently across timelines. Plasma GFAP was the earliest biomarker to become abnormal in the tau timeline. The plasma Aβ42/Aβ40 levels reached a plateau, while plasma p-tau217, p-tau181, GFAP and NfL increased throughout disease progression. Some differences in the timing of change were observed across biomarker assays.
The primary utility of plasma Aβ42/Aβ40 may lie in early identification of individuals at high risk of AD. In contrast, p-tau217, p-tau181, GFAP and NfL increase throughout the estimated timelines, supporting their potential as biomarkers for staging and monitoring disease progression.
Competing Interest Statement
Suzanne E. Schindler (S.E.S.) has no financial interests in any pharmaceutical companies and has not received any direct research funding from any pharmaceutical companies. S.E.S. has served on scientific advisory boards on biomarker testing and education for Eisai and Novo Nordisk and has received speaking fees for presentations on biomarker testing from Eisai, Eli Lilly, and Novo Nordisk. Henrik Zetterberg (H.K.) has no financial interests in any pharmaceutical companies and has not received any direct funding from any pharmaceutical companies. H.K. has served on scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, Roche, and WebMD, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). Janaky Coomaraswamy (J.C.), Michael Baratta (M.B.), and David L. Raunig (D.L.R.) receive salary and company stock as compensation for their employment with Takeda Pharmaceutical Company Limited. Marta Mila-Aloma (M.M.A.), Kellen K. Petersen (K.K.P.), Benjamin Saef (B.S.), Duygu Tosun (D.T.), Zachary Hausle (Z.H.), and Erin G. Rosenbaugh (E.G.R.) have nothing to disclose. Leslie M. Shaw (L.M.S.) receives funding from the NIA for ADNI4 and from NIA for the University of Pennsylvania ADRC P30 for the Biomarker Core. Jeffrey L. Dage (J.L.D.) is an inventor on patents or patent applications of Eli Lilly and Company relating to the assays, methods, reagents, and/or compositions of matter for P-tau assays and Aβ targeting therapeutics. J.L.D. has served as a consultant or on advisory boards for Eisai, Abbvie, Genotix Biotechnologies Inc, Gates Ventures, Karuna Therapeutics, AlzPath Inc., Cognito Therapeutics, Inc., and received research support from ADx Neurosciences, Fujirebio, AlzPath Inc., Roche Diagnostics and Eli Lilly and Company in the past 2 years. J.L.D. has received speaker fees from Eli Lilly and Company. J.L.D. is a founder and advisor for Monument Biosciences. J.L.D. has stock or stock options in Eli Lilly and Company, Genotix Biotechnologies, AlzPath Inc. and Monument Biosciences. Kyle Ferber (K.F.) and Carrie E. Rubel (C.E.R.) are employees of and may own stock in Biogen. Gallen Triana-Baltzer (G.T.B.) and Ziad S. Saad (Z.S.S.) are employed by Johnson & Johnson Innovative Medicine and may receive salary and stock for their employment. Lei Du-Cuny (L.D.C.) and Yulia Mordashova (Y.M.) are employed by AbbVie Deutschland GmbH & Co. Yan Li (Y.L.) is the co-inventor of the technology "Novel Tau isoforms to predict onset of symptoms and dementia in Alzheimer's disease" which is in the process of licensing by C2N. Nicholas J. Ashton (N.J.A) has received speaking fees from Eli Lilly, Biogen, Quanterix and Alamar Biosciences. Emily A. Meyers (E.A.M.) is employed by the Alzheimer's Association. Anthony W. Bannon (A.W.B.) receives salary and company stock as compensation for his employment with AbbVie Inc. William Z. Potter (W.Z.P.) was previously employed by the National Institute of Mental Health, and he is a stockholder in Merck & Co., Inc. W.Z.P. is a Co-Chair Emeritus for the FNIH Biomarkers Consortium Neuroscience Steering Committee. Currently residing in Philadelphia, PA, W.Z.P. serves as a consultant for Karuna, Neurocrine, Neumarker, Vaaji, and receives grant support from the NIA along with stock options from Praxis Bioresearch.
Funding Statement
The results of the study represent results of the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium "Biomarkers Consortium, Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer's Disease" project. The study was made possible through the scientific and financial support of industry, academic, patient advocacy, and governmental partners. We are grateful for the contributions of the following project team members: Anthony Bannon (AbbVie), Michael Baratta (Takeda), Janaky Coomaraswamy (Takeda), Jeff Dage (Indiana University), Iwona Dobler (Takeda), Lei Du-Cuny (AbbVie), Kyle Ferber (Biogen), John Hsiao (NIA), Hartmuth Kolb (formerly with Johnson and Johnson Innovative Medicine), Emily Meyers (Alzheimer's Association), Yulia Mordashova (AbbVie), William Potter, Maria Quinton (AbbVie), Dave Raunig (Takeda), Erin Rosenbaugh (FNIH), Carrie Rubel (Biogen), Ziad Saad (Johnson and Johnson Innovative Medicine), Patricia Saletti (Alzheimer's Drug Discovery Foundation), Suzanne Schindler (Washington University in St. Louis), Leslie Shaw (University of Pennsylvania), Gallen Triana-Baltzer (Johnson and Johnson Innovative Medicine), Christopher Weber (Alzheimer's Association), Henrik Zetterberg (University of Gothenburg). Funding partners of the project include AbbVie Inc., Alzheimer's Association®, Diagnostics Accelerator at the Alzheimer's Drug Discovery Foundation, Biogen, Janssen Research & Development, LLC, and Takeda Pharmaceutical Company Limited. Private-sector funding for the study was managed by the Foundation for the National Institutes of Health. We recognize C2N Diagnostics, Fujirebio Diagnostics with the Indiana University National Centralized Repository for Alzheimer's Disease and Related Dementias Biomarker Assay Laboratory (NCRAD-BAL), Quanterix, and Roche Diagnostics with the University of Gothenburg for performing the plasma biomarker analysis in this study. The NCRAD-BAL is supported by a cooperative agreement grant (U24 AG021886) awarded to NCRAD by the National Institute on Aging. Elecsys β-amyloid (1-42) CSF, Elecsys Phospho-Tau (181P) CSF and Elecsys Total-Tau CSF assays are approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. The NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders, used for research purposes only and not approved for clinical use (Roche Diagnostics International Ltd, Rotkreuz, Switzerland). Finally, we would like to acknowledge ADNI for the plasma samples and ADNI participant data analyzed in this study. Data collection and sharing for the Alzheimer's Disease Neuroimaging Initiative (ADNI) is funded by the National Institute on Aging (National Institutes of Health Grant U19 AG024904). The grantee organization is the Northern California Institute for Research and Education. In the past, ADNI has also received funding from the National Institute of Biomedical Imaging and Bioengineering, the Canadian Institutes of Health Research, and private sector contributions through the Foundation for the National Institutes of Health (FNIH) including generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company Limited; and Transition Therapeutics. M.M.A receives funding from the Alzheimer's Association Research Fellowship grant program (AARF-23-1141384). Statistical analyses were supported in part by National Institute on Aging grant R01AG070941 (S.E.S.). The Biomarkers Consortium, Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer's Disease Project was made possible through a public-private partnership managed by the Foundation for the National Institute of Health (FNIH) and funded by AbbVie Inc., Alzheimer's Association®, Diagnostics Accelerator at the Alzheimer's Drug Discovery Foundation, Biogen, Janssen Research & Development, LLC, and Takeda Pharmaceutical Company Limited. Data used in the preparation of this article were obtained from the ADNI database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in the analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵** Alzheimer’s Disease Neuroimaging Initiative (ADNI): Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at:http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
Data availability
Data from this study and the study methodology report may be accessed from the ADNI Laboratory of Neuro Imaging (LONI) database: adni.loni.usc.edu.
